BRIAN CRONK: Open Payments
NPI 1760583785 · FORT COLLINS, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,127 in 137 payments from 19 companies in 2025. Trend: 2023 $2,419 · 2024 $3,497 · 2025 $3,127
Food & beverage: $3,127
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $656 |
| Gilead Sciences, Inc. | 17 | $483 |
| Janssen Biotech, Inc. | 14 | $335 |
| Madrigal Pharmaceuticals | 7 | $232 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $217 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $204 |
| Ardelyx, Inc. | 6 | $194 |
| Regeneron Healthcare Solutions, Inc. | 7 | $185 |
| QOL Medical, LLC | 9 | $168 |
| GENZYME CORPORATION | 6 | $161 |
Products named: TREMFYA, DUPIXENT, RINVOQ, REZDIFFRA, XIFAXAN, IBSRELA, LINZESS, Sucraid.
Industry payments across CO — which companies pay providers there.
